MiNK Therapeutics Inc. Stock Price, News, Quote & History

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

MiNK Therapeutics Inc.

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer Meeting

MiNK Therapeutics Appoints Colonel John B. Holcomb, MD, to Board of Directors

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

5 US Longevity and Anti-aging Stocks to Watch in 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

Uranium Energy Corp Applauds U.S. Government's Designation of Uranium as a Critical Mineral

Star Royalties Highlights Copperstone Development Progress and Exploration Potential

New Break Resumes Drilling in the Zavitz Discovery Zone at the Moray Gold Project

TELUS Corporation - NOTICE OF CASH DIVIDEND

Latest News

Outlook Reports world

Featured Biotech Investing Stocks

Browse Companies